Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.
Beginning six months of treatment within two days following infection prevented viral rebound in at least some animals in a recent study.
However, the regimen appears much less potent for those who aren’t virally suppressed.
Biktarvy has a lower rate of adverse health events, according to 96-week data.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
Researchers argue that among children born to mothers with HIV, other factors such as the virus and substance use prompt such outcomes.
So argued researchers behind a study that switched people from triple-antiretroviral regimens to Tivicay monotherapy.
This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.
People who take integrase inhibitors are less likely to stop them due to health issues.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
Researchers presented 100-week data on a trial of the antiretroviral (ARV) regimen at the international AIDS conference.
Full 48-week results comparing Tivicay plus Epivir with Tivicay plus Truvada were presented at the International AIDS Conference.
A large ongoing study in Botswana has found that about 1 in 150 babies exposed to Tivicay at conception developed such birth defects.
Tivicay (dolutegravir) is a next-generation integrase inhibitor.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.